Search Results - dejene+tufa

1 Results

Sort By:

Innate Lymphoid Cell (ILC) Therapy for GvHD

High refractory and mortality of GvHD Hematopoietic stem cell transplantation (HSCT) is curative for a variety of malignant and non-malignant disorders with no other therapeutic options. Graft versus host disease (GvHD) accounts for morbidity and mortality after HSCT. GVHD occurs in 30 to 60% of HSCT cases and carries approximately a 50% mortality rate....

Published: 10/23/2023 | Inventor(s): Michael Verneris, Dejene Tufa

Disease Areas Immunology, Oncology

Category(s): Therapeutics